LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.43% | 8.76% | 444.30% | 50.18% | 51.15% |
| Total Depreciation and Amortization | 102.06% | 65.68% | 89.24% | 0.31% | 17.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.09% | 36.22% | -222.18% | 8.48% | 95.82% |
| Change in Net Operating Assets | 161.02% | 81.37% | 86.36% | 78.79% | -290.25% |
| Cash from Operations | 1,474.42% | 124.69% | 3,263.54% | 96.47% | -1,267.16% |
| Capital Expenditure | 53.16% | 29.59% | 952.17% | -532.23% | -296.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -165.43% | -159.65% | -552.19% | -558.06% | -1,905.41% |
| Cash from Investing | 69.91% | -10.51% | -379.61% | -549.27% | -1,223.78% |
| Total Debt Issued | 1,184.93% | 199.24% | 692.76% | -40.27% | -47.54% |
| Total Debt Repaid | 36.22% | -45.80% | -232.65% | -480.00% | -229.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.30% | -95.10% | -163.02% | 40.74% | -84.82% |
| Cash from Financing | 15.74% | -2.86% | 285.62% | -36.33% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,371.95% | 5,455.26% | 237.99% | 77.46% | 236.80% |